Navigation Links
GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
Date:4/7/2011

ATLANTA, April 7, 2011 /PRNewswire/ -- Harriet Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), will provide an update on the status of the Company's therapeutic and preventative HIV vaccines at the 2011 World Vaccine Conference at the Gaylord National Hotel and Convention Center in Washington DC on Thursday, April 14.  Dr. Robinson's invited talk, which will run from 11:30 – 11:50 a.m., will cover the topic of recombinant viruses as vaccines. The talk will be followed by a Q&A session at 12:30 pm.

GeoVax has a multi-protein clade B HIV/AIDS vaccine in an open-label Phase 1/2 therapeutic trial and in a double-blinded, 300-participant Phase 2a preventative trial.  The preventative trial is being conducted and supported by the US HIV Vaccine Trials Network (HVTN). The vaccine was developed in Dr. Robinson's former laboratory at the Emory Vaccine Center in collaboration with Dr. Bernard Moss's laboratory at the US National Institutes of Health and researchers at the US Centers for Disease Control and Prevention.  Recently, the Company announced a 70% prevention rate in a non-human primate study using their GM-CSF co-expressing  vaccine.  This represents the highest successful prevention rate ever achieved in such a non-human model with a preventative vaccine for HIV.

Dr. Robinson, formerly Asa Griggs Candler Professor of Microbiology and Immunology at Emory University and Chief of the Division of Microbiology and Immunology at the Yerkes National Primate Research Center, is internationally recognized for her work on HIV/AIDS vaccines, her pioneering studies on the use of recombinant DNA for vaccination and her seminal studies on insertional mutagenesis and oncogene transduction in retroviral induced cancers. She received her Ph.D. from the Massachusetts Institute of Technology and her postdoctoral training at the Virus Laboratory, University of California Berkeley. Dr. Robinso
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
2. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
3. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
4. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
5. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
6. GeoVax Labs Engages The Investor Relations Group
7. GeoVax Labs, Inc. Reports Fourth Quarter and Year End 2009 Financial Results
8. GeoVax Labs, Inc. Plans Public Offering
9. GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA
10. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
11. GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  ViaCyte, Inc., a privately-held regenerative medicine ... treatment of diabetes in clinical trials, today announced the opening of ... or S afety, T olerability, and E fficacy ... Diabetes.  The new site, which is the first in ... in Edmonton , Alberta.  The ...
(Date:7/29/2015)... July 29, 2015  Fifty groups representing 500,000 patients, ... 29, to launch the AllTrials campaign in the US. ... present, and future, to be registered and the results ... Ben Goldacre explains: "Patients want the treatments ... evidence on what works. Unfortunately, we now know that ...
(Date:7/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/hmjqff/global_wound_care ) has ... Care Markets (Twelve Country Analysis: Germany, France, Italy, ... Brazil, Australia, South Korea)" report to their ... competitive market summary. The wound care market is ... product maturity. Several of the products within the ...
Breaking Medicine Technology:ViaCyte Announces Second Clinical Trial Site at University of Alberta 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 3ViaCyte Announces Second Clinical Trial Site at University of Alberta 4Fixing Your Medicine: AllTrials Campaign Launches in US 2Fixing Your Medicine: AllTrials Campaign Launches in US 3Global Wound Care Markets 2015 2
... 29, 2011 , OBN BioCluster ... The UK bioindustry has raised over $250m in financing during the ... for one year, and the second largest amount raised in any ... financing drought that saw three consecutive quarters below $100m from the ...
... 29, 2011 Sales executives agree that delivering ... biopharmaceutical sales process. Yet despite the effectiveness of ... drug,s efficacy, only 6% of biopharmaceutical district sales ... of data to sales representatives, according to recent ...
Cached Medicine Technology:UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 2UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 3Though Essential to Pharmaceutical Sales Success, the Use of Health Outcomes Data Often Overlooked by Sales Leaders 2
(Date:7/29/2015)... CA (PRWEB) , ... July 29, 2015 , ... We are privileged to announce that ... Medicine of USC as the ninth best ophthalmology hospital in the nation for 2015-2016. This ... 10 American hospitals for ophthalmology. , “It is an honor to be included in ...
(Date:7/29/2015)... ... July 29, 2015 , ... Inspired by a successful ... Steven W. Meier M.D., a prominent orthopedic surgeon and regenerative medicine expert in ... financial need. , “We are thrilled for this opportunity to offer prolotherapy treatments ...
(Date:7/29/2015)... ... July 29, 2015 , ... Stealth ... a Clinical Performance Study for the Invisiport at Wheaton Franciscan Healthcare in Milwaukee, ... options, offers a less invasive, patient-friendly alternative to traditional chest ports and peripherally ...
(Date:7/29/2015)... ... July 29, 2015 , ... Zofran ... Judicial Panel on Multidistrict Litigation (JPML), according to court documents.* Attorneys handling ... website, the Zofran Birth Defects Lawsuit Center. , GlaxoSmithKline, the global pharmaceutical conglomerate ...
(Date:7/29/2015)... ... July 29, 2015 , ... The Woodlands and Spring ... lifestyles while donating to worthy charitable causes each month. The new system will track ... camp. For each Check In at each facility, the boot camps will donate 20 ...
Breaking Medicine News(10 mins):Health News:21 Years & Counting: The USC Eye Institute Ranks in the Top 10 Ophthalmology Hospitals in America 2Health News:21 Years & Counting: The USC Eye Institute Ranks in the Top 10 Ophthalmology Hospitals in America 3Health News:Orthopedic Surgeon Announces New Pro Bono Prolotherapy and Regenerative Medicine Clinic for Underserved Communities in Los Angeles 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 2Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 3
... your keys has its down sideSAN FRANCISCO, March 13 ... (Medical Sciences) indicate that convincing older drivers to give up ... study of 660 adults aged 63 to 97 showed that ... likely to die over a three-year period than their counterparts ...
... - The Boston Center for Refugee Health and ... treated many of the large number of Tibetan ... individuals arrived in Boston suffering from symptoms of ... monks were diagnosed by their traditional healers as ...
... - Haemacure Corporation (TSX : HAE) released today ... 31, 2009.ResultsRevenues amounted to $19,226, as compared to ... were exclusively derived from the sale of legacy ... $2.7 million, up from $1.2 million for the ...
... half of Americans know that the "better" fats (monounsaturated ... disease, according to a recent survey by the American ... at: http://inr.mediaseed.tv/aha_36307/ "Heart disease remains the No. ... lot about the ,bad, fats lately and what not ...
... occurred in ICUs , , THURSDAY, March 12 (HealthDay News) ... problem in intensive care units, a new study reveals. ... ICUs in 27 countries over a 24-hour period in ... included in the study. , Dr. Andreas Valentin of ...
... MESSA,s East Lansing-based ... consecutive year for superior efficiency and performance in providing ... providing efficient and effective customer service as measured against ... at Purdue University and BenchmarkPortal. "MESSA is ...
Cached Medicine News:Health News:Drive or Die 2Health News:Drive or Die 3Health News:Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks 2Health News:Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks 3Health News:Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company 2Health News:Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company 3Health News:VIDEO From Medialink and the American Heart Association: 'Better Fats' Benefit Heart Health 2Health News:Injected Medication Errors a Major Problem 2Health News:MESSA Receives National Recognition for Best Practices in Providing Efficient, Cost-Effective Customer Service 2Health News:MESSA Receives National Recognition for Best Practices in Providing Efficient, Cost-Effective Customer Service 3
... HmX offers three-dimensional ... sensitivity, specificity and efficiency ... and reticulocyte analysis. With ... and dependability, HmX is ...
Creatinine Test Kit (enzymatic), Wavelength: 340 nm. Linear range: up to 20 mg/dL....
For the quantitative determination of Creatine Kinase in serum....
For the qualitative determination of magnesium in serum....
Medicine Products: